The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers. Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Pancreatic adenocarcinoma (PDAC) remains one of the deadliest cancers, with survival rarely exceeding a few months and limited progress despite improved chemotherapy. Its poor prognosis is driven by late diagnosis, therapeutic resistance, and low responsiveness to targeted therapies and immunotherapy. PDAC is characterized by a dense, immunosuppressive stroma and severe metabolic stress due to poor vascularization. Tumor progression relies heavily on stromal cells-such as cancer-associated fibroblasts and macrophages-as well as metabolic adaptations of cancer cells. This project focuses on two key PDAC features to identify new biomarkers and therapeutic targets: * Stromal cell prevalence * Metabolic reprogramming
Study Type
OBSERVATIONAL
Enrollment
64
Tumor cells isolation
Isolation of blood monocytes
Institut Paoli-Calmettes
Marseille, France
RECRUITINGEvaluation and comparison of biological parameters reflecting metabolic alterations within the tumor microenvironment of pancreatic adenocarcinoma
* Assessment of stromal dependency mechanisms; * Characterization and comparison of the metabolic profiles of primary pancreatic tumors and associated liver and lung metastases. These analyses aim to identify potential therapeutic targets and to explore diagnostic, prognostic, and predictive biomarkers of treatment response.
Time frame: From sample collection to completion of analyses, estimated at 3 years
Exploratory characterization of metabolic pathways, tumor microenvironment features, and associated biomarkers in pancreatic adenocarcinoma.
* Identification of prognostic markers of therapeutic response originating from the tumor microenvironment. * Identification of mechanisms of resistance to anti-tumor treatments linked to the microenvironment. * Identification of new therapeutic strategies capable of specifically targeting the tumor microenvironment.
Time frame: From sample collection to completion of analyses, estimated at 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.